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Abstract: Problem statement: Upper Respiratory Tract Infections (URTIs) are the most frequent of 
the community with major social and financial impact. Hence, early and proper diagnosis is of utmost 
importance. Biomarkers such as the circulating levels of Procalcitonin (PCT) have been shown to be 
elevated in systemic bacterial infections, but remain relatively low in viral infections and inflammatory 
diseases and have been suggested as signals for the initiation of antimicrobial therapy. Experience 
evaluating the value of PCT as a marker of URTIs is limited. Approach: Forty patients with bacterial 
URTIs were studied in order to assess the role of PCT, measured by using the semi-quantitative test, as 
bacterial inflammation marker and to compare with other markers, such as C-Reactive Protein (CRP), 
White Blood Cell (WBC) counts and Polymorphonuclear (PMN) cell counts. Results: In all cases, 22 
with tonsillopharyngitis, 10 with peritonsillar abscess and 8 with rhinosinusitis, PCT levels remained 
below detection limits. On the other hand, serum CRP levels strongly correlated with body temperature, 
WBC and PMN cell counts. Patients with rhinosinusitis were older than those with peritonsillar abscess, 
had lower body temperature than those with tonsillopharyngitis and had lower serum CRP levels than 
patients with either peritonsillar abscess or tonsillopharyngitis. Conclusion: Therefore CRP could be 
used as a marker to predict the severity of URTIs while PCT, although promising in cases of other 
severe  bacterial  infections,  did  not  prove  to  be  suitable  for  patients  with  less  severe  or  localized 
infections, such as URTIs. 
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INTRODUCTION 
 
  Upper Respiratory Tract Infections (URTIs) are the 
most frequent infections of the community, with major 
social  and  financial  impact
[1].
  They  represent  a 
heterogeneous group of diseases ranging from common 
cold  to  complicated  rhinosinusitis  and  acute  otitis 
media.  The  main  challenge  for  the  physician  is  to 
distinguish  the  uncomplicated  cold  from  cases  of 
streptococcal  pharyngitis  and  secondary  bacterial 
sinusitis  and  otitis  media  in  order  to  avoid 
overprescribing  of  antibiotics,  limit  complications, 
costs  and  selection  of  resistant  microorganisms.  It  is 
estimated  that  physicians  in  such  cases  overprescribe 
antibiotics by 50%
[2-4].  
  Among  URTIs  tonsillopharyngitis,  peritonsillar 
abscess  and  rhinosinusitis  account  for  a  significant 
number of infections of bacterial origin. The diagnosis is 
mainly based on clinical criteria, especially in an ENT 
outpatient office. The  most precise  way  to diagnose a 
bacterial infection is by culture of the causative agent
[5-7]. 
However,  a  novel  approach  for  confirmation  of  the 
bacterial  origin  of  infections  and  proper  selection  of 
antimicrobial therapy is based on the level of biomarkers, 
specifically Procalcitonin (PCT)
[8-15]. 
  Circulating levels of PCT are elevated in systemic 
bacterial  infections  but  remain  relatively  low  in  viral 
infections and inflammatory diseases
[8-15].  
  Hence, the aim of the current study was to assess 
the role of PCT as a bacterial inflammation marker in 
patients  with  tonsillopharyngitis,  rhinosinusitis  and 
peritonsillar abscess and compare it with other markers, 
such  as  CRP,  White  Blood  Cells  (WBC)  and 
Polymorphonuclear (PMN) cell counts.  Am. J. Infect. Dis., 5 (4): 282-287, 2009 
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MATERIALS AND METHODS 
 
  The  study  was  performed  prospectively  at  the 
University  Hospital  of  Heraklion  Crete,  Greece,  was 
approved by the Ethics Committee, while consent was 
obtained by all patients. Subjects were first seen at the 
ENT outpatient clinic and were treated either as out-or 
inpatients according to standard protocols. 
  A  total  of  40  individuals  were  enrolled,  divided 
into  three  groups  according  to  clinical  diagnosis: 
Tonsillopharyngitis   (n = 22),   peritonsillar    abscess 
(n = 10) and bacterial rhinosinusitis (n = 8).  
  Diagnosis of tonsillopharyngitis was based on pain 
and difficulty in swallowing, otalgia, fever (>38.5°C) 
accompanied by rigor, change in voice, tender cervical 
lymph nodes and swollen reddish tonsils with whitish 
exudate. 
  Diagnosis  of  peritonsillar  abscess  was  based  on 
pus, located deep into the tonsillar capsule between the 
tonsil and the superior constrictor muscle, deviation of 
the tonsil and uvula, swelling of the soft palate, trismus 
and drooling. Diagnosis was established by culture of 
aspiration specimen. 
  Diagnosis  of  rhinosinusitis  was  based  on  the 
presence  of  at  least  two  symptoms,  such  as  nasal 
blockage  or  congestion,  anterior  discharge  or  post 
nasal drip, facial pain or pressure and reduction or loss 
of  smell  accompanied  by  endoscopic  signs  and/or 
relevant computed tomography findings, according to 
the  criteria  of  the  European  rhinosinusitis 
Committee
[16]. 
  All  patients  were  interviewed  and  a  detailed 
medical  history  was  obtained,  including  demographic 
data (age, sex, occupation, residence), medical history, 
symptoms and use of medication with focus on use of 
antimicrobials. Body temperature was recorded at the 
time of initial examination. A full and thorough head 
and  neck  physical  examination  was  performed  and 
recorded.  Patients  were  treated  as  out  or  in-patients 
according to the severity of the infection. All patients 
were immunocompetent,  with no concurrent diseases, 
except  for  one  with  bronchial  asthma.  Antimicrobial 
treatment was initiated or continued in all patients after 
the first examination. 
  Specimens  were  cultured  from  all  patients, 
including  tonsillar  swabs  from  those  with 
tonsillopharyngitis,  aspirated  pus  from  those  with 
peritonsillar abscess and secretions from middle meatus 
from  those  with  rhinosinusitis.  All  samples  were 
inoculated onto Columbia blood agar, chocolate agar, 
MacConkey  agar  and  Sabouraud’s  agar  plates  (all 
media  products  of  Becton  Dickinson  Diagnostics, 
Heidelberg,  Germany)  and  incubated  in  aerobic 
atmosphere at 36°C. Additionally, one CDC-anaerobic 
blood agar plate (bioMérieux, Marcy L’ Etoile, France) 
was inoculated and incubated anaerobically at 36°C for 
48 h. The identification of pathogens was performed by 
standard microbiological methods and the API system 
(bioMerieux,  Marcy  L’  Etoile,  France).  Susceptibility 
to  antimicrobial  agents  was  determined  by  the  disk 
diffusion  method  recommended  by  the  Clinical  and 
Laboratory Standards Institute (CLSI). 
  Blood samples were obtained from all patients for 
complete  blood  count,  CRP  and  PCT.  PCT 
measurement was based on the BRAHMS PCT-Q test, 
which is an immunochromatografic test for the semi-
quantitative detection of PCT for diagnosis and control 
of therapeutic results in cases of  microbial infections 
and sepsis.  
 
Statistical  analysis  and  presentation  of  results: 
Values  are  expressed  as  median  and  range.  All  p 
values  are  two-tailed.  Correlation  was  assessed  by 
Spearman's  correlation  (rs).  Results  between  groups 
were  assessed  by  Mann-Whitney  tests.  Frequency 
analysis  was  assessed  by  c
2  test,  with  Yate’s 
correction. A p-value less than 0.05 was regarded as 
statistically significant. 
 
RESULTS 
 
  The  study  comprised  of  40  patients,  24  male 
(60%) and 16 female (40%) with a median age of 25 
(range: 16-56) years. Fever upon admission was seen 
in 34 patients (85%). Among the 40 patients, 10 (25%) 
were  diagnosed  with    peritonsillar  abscess,  all  of 
whom had positive cultures, while 80% of them had 
been  taking  antibiotics  for  at  least  one  day  prior  to 
first examination. Streptococcus spp. were isolated in 
4    patients,    Fusobacterium    necrophorum  in  3 
patients,  while  Arcanobacterium  haemoliticus, 
Prevotela loescheii and Haemophilus influenzae were 
the strains isolated from each of the rest patients with 
peritonsilar abscesses.  
  Eight out of 40 patients (20%) were diagnosed with 
rhinosinusitis. Among them 2 (25%) were already taking 
antimicrobial treatment at the time of first examination. 
Only 3 out of 8 patients with rhinosinusitis (37.5%) had 
a  positive  culture.  The  organisms  isolated  were 
Escherichia  coli,  Streptococcus  pneumoniae  and 
Staphylococcus epidermidis. The remaining 22 patients 
(55%)  had  tonsillopharyngitis.  Among  them,  10 
(45.5%) had a positive culture. Streptococcus pyogenes 
grew  in  all  of  them.  Eight  patients  with 
tonsillopharyngitis  (36.4%)  were  taking  antimicrobial 
therapy at the time of first examination.  Am. J. Infect. Dis., 5 (4): 282-287, 2009 
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Table 1: Patient’s characteristics 
   Peritonsillar abscess  Rhinosinusitis  Tonsillopharyngitis 
  (n = 10)  (n = 8)  (n = 22) 
Age (years)  22  31**  24 
Range  (16-33)  (23-42)  (17-56) 
Men  6  5  13 
Percent  -60  -62.50  -59.10 
Body temperature  38.2  37.6  38.5* 
(°C range)  (36.8-39.2)  (36.4-38.7)  (36.5-39.6) 
Positive culture  10**  3  10 
Percent  -100  -37.50  -45.50 
Already  8*  2  8 
Receiving  -80  -25  -36 
antibiotics (%) 
CRP (mg mL
-1)  13.9  1.77**  8.52 
range  (1.20-24.10)  (0.12-9.80)  (0.31-22.60) 
WBC ( L
-1)  17150  11900*  14500 
range  (7700-23500)  (8000-13400)  (7900-25000) 
PMN ( L
-1)  13969  8418*  11427 
range  (5159-19270)  (5200-11500)  (5336-21500) 
CRP:  C-Reactive  Protein;  WBC:  White  Blood  Cell  count;  PMN: 
Polymorphonuclear cell count; *: p<0.05; **: p<0.01; All values are 
expressed as number (%) or median (range). Between group results 
were  compared  by  Mann-Whitney  test  or  by  χ
2  test  with  Yate’s 
correction, as appropriate 
   
  Patients with rhinosinusitis were older than those 
with peritonsillar abscess (p = 0.01), had lower body 
temperature  than  those  with  tonsillopharyngitis 
(p<0.05) and had lower serum CRP levels than patients 
with  either  peritonsillar  abscess  (p<0.01)  or 
tonsillopharyngitis (p<0.01). There was no difference in 
the sex distribution between the 3 groups (Table 1). 
  Overall  22  patients  (55%)  was  not  under 
antimicrobial treatment on initial examination, whereas 
11 (27.5%) and 7 (17.5%) had received antibiotics for 
one and two days prior to examination, respectively. In 
23  patients  (57.5%)  a  causative  microorganism  grew 
from  specimens  sent  for  culture.  Patients  with 
rhinosinusitis  had  lower  WBC  (p<0.05)  and  PMN 
(p<0.05) counts and CRP serum levels (p<0.01) than 
both other groups (Table 1).  
  Serum  CRP  levels  were  significantly  correlated 
with  body  temperature  (rs = 0.553;  p<0.001), WBC 
(rs = 0.560; p<0.001), PMN (rs = 0.594; p<0.001). Body 
temperature  was  correlated  with  WBC  (rs  =  0.339; 
p<0.05)  and  PMN  (rs  =  0.367;  p<0.05).  In  all  cases 
measurement of PCT yielded levels below 0.5 ng mL
-1, 
which  is  the  detectable  limit.  All  patients  received 
antimicrobial therapy after initial examination.  
  On  follow  up,  performed  1-3  weeks  after  initial 
examination,  no sequelae  were noted and all patients 
were  free  of  any  clinical  signs  and  symptoms  of 
infection. 
 
DISCUSSION 
 
  In the present study we have shown that PCT was 
not proven to be a marker of bacterial URTIs  while, 
CRP could be used as a marker of severity of these type 
of infections. 
  URTIs are common with substantial financial and 
social  costs
[1].  Though  mainly  viral  in  origin,  their 
etiologic diagnosis is seldom and the pathogen remains 
unidentified in many cases
[5-7]. The clinical diagnosis of 
a  bacterial  URTI  is  a  challenge  even  for  the  most 
experienced  physician.  Hence,  several  diagnostic 
markers have been tested for their efficacy to accurately 
distinguish bacterial from non-bacterial disease. These 
markers include WBC count and other biomarkers such 
as  troponin,  B-type  Natriuretic  Peptide  (BNP),  N-
terminal  proBNP,  CRP,  PCT,  cholesterol  and 
coagulation related markers
[13]. The goal is to limit the 
use of antimicrobials and the concurrent development 
of  bacterial  resistance.  Additionally  there  is  always 
need for the physician to predict whether a URTI may 
become  complicated,  especially  in  susceptible 
populations, such as children and the elderly. 
  Among the proposed markers for rapid distinction 
between  bacterial  and  non-bacterial  etiology,  PCT  is 
thought to be the most promising for infections of the 
upper  respiratory  tract
[12-15].  There  are  four  available 
commercial kits for the measurement of PCT
[17]. The 
semi-quantitative test (BRAHMS PCT-Q), was used in 
the present study because it is cheap, easy, suitable for 
office procedures and fast, since results are available in 
less than an hour. The BRAHMS PCT-Q test has 90-
92%  sensitivity  and  92-98%  specificity  and  detects 
PCT levels above 0.5 ng mL
-1[15]. 
  PCT  is  a  protein  of  116  amino-acids,  with 
molecular  weight  of  13  KDa,  discovered  in  1975  by 
Moya et al.
[18], as a prohormone of calcitonin, produced 
by C-cells of the thyroid. Experimental data from both 
in vivo and in vitro studies have shown that not only 
bacterial endotoxins, but also various other mediators, 
such  as  TNFα,  IL-2,  IL-6  and  phytohemagglutinin 
induce  PCT  production
[19,20].  After  administration  of 
endotoxin, TNF rises first, reaching its peak in 90 min, 
followed by IL-6 with its peak at 180 min, while PCT 
reacts only after 3-6 h later
[21]. Due to their long half-
life,  PCT  levels  culminate  12-48  h  after  the 
administration of endotoxin. The probable sites of PCT 
production in inflammation are the neuroendocrine cells 
in the lungs or intestine, when stimulated by endotoxin 
or inflammatory cytokines. Once induced, PCT acts as 
a chemokine in the area of production, attracting further 
monocytes,  lasting  for  a  few  hours.  Later  on, 
parenchymatous  cells  are  a  major  source  for  PCT 
during sepsis, but only when they come in contact with 
activated monocytes
[21].  
  The  biological  activity  of  PCT  has  significant 
influence on the course of systemic inflammation and Am. J. Infect. Dis., 5 (4): 282-287, 2009 
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sepsis.  The  mortality  of  hamsters  decreased  when 
calcitonin precursors were neutralized
[22]. On the other 
hand  sepsis,  infections,  prolonged  ICU  treatment  and 
poor  outcome  were  more  frequent  in  patients  with 
initially  high  PCT  (>1  ng  mL
-1).  Higher  PCT 
concentrations  correlate  with  severe  trauma  and  a 
higher  frequency  of  complications,  whereas  increases 
of  CRP  showed  no  positive  correlation  in  trauma 
patients
[22].  Long  before  PCT,  WBC  count  has  been 
used as an indicator of both infection and its severity. 
WBC elevation, while worrisome, is neither sensitive 
nor specific indicator of bacteremia and other serious 
bacterial infection
[23]. PMN cell count is a fraction of 
WBC’s and is considered to be a more accurate marker 
of bacterial infection.  
  CRP is an acute phase protein that quickly rises in 
the  face  of  infection.  First  was  discovered  by  Tillet 
and  Francis   in   1930,  in   patients   infected   with 
S.  pneumoniae
[24].  It  appears  to  be  produced  by 
hepatocytes within 4-6 h after onset of tissue injury or 
inflammation,  doubling  every  8  h,  before  peaking  at 
around 36 h. Its half-life is short (4-8 h)
[24-26]. CRP is 
synthesized in response to IL-6, which is produced not 
only  in  infection,  but  also  in  other  types  of 
inflammation
[27].  It  binds  to  polysaccharides  in 
pathogens,  thus  activating  the  classical  complement 
pathway.  
  PCT  and  CRP  have  been  used  as  markers  for 
distinguishing  bacterial  from  viral  infections
[10,12,22]. 
Based on data from a meta-analysis Simmon et al.
[28] 
have found that PCT as a marker has a sensitivity of 
92%  and  specificity  of  73%,  whereas  CRP  a 
sensitivity of 86% and specificity of 70%. This means 
that  when  a  bacterial  infection  is  suspected, 
measurement of PCT would be the most accurate way 
of verification. 
  In the present study patients with bacterial URTIs, 
were enrolled. Usual clinical criteria were used for the 
diagnosis.  In  all  cases  measurement  of  PCT  yielded 
levels  below  0.5  ng  mL
-1,  which  is  the  lowest 
concentration that can be traced.  
  Few studies exist in the literature regarding URTIs 
and PCT levels. Elsammak et al.
[29] studied PCT and 
CRP in children with tonsillopharyngitis, using the PCT 
LUMItest.  They  found  that  median  levels  of  PCT  in 
children  with  Streptococcal  tonsillopharyngitis 
compared  to  non  bacterial  tonsillopharyngitis  were 
0.374 and 0.105 ng mL
-1 respectively PCT also had a 
greater sprcificity than CRP for detection of bacterial 
tonsillopharyngitis.  
  All patients in our series had PCT levels below 
0.5 ng mL
-1. The low levels of PCT could be attributed 
to two main reasons. First, blood samples might have 
been taken later than the peak of PCT, which is 6-8 h 
after the onset of infection, while 48 h later PCT falls 
below  1  ng  mL
-1,  especially  when  antibiotics  have 
already been administered, as in many of our cases (11 
out of 23)
[30]. Second, sensitivity of the PCT-Q test in 
localized  infections  of  moderate  severity  such  as 
URTIs  is  usually  lower,  compared  to  patients  with 
generalised  infections  and  positive  blood  cultures. 
Therefore,  subtle  elevations  of  circulating  PCT,  are 
not detected
[30].  
  It  is  of  interest  that  even  in  peritonsillar  abscess 
cases,  a  most  severe  infection  compared  to 
tonsillopharyngitis and rhinosinusitis, PCT levels were 
below detection limit. On the other hand, WBC, PMN, 
CRP and body  temperature  were more elevated in 
this group than in the others. The fact that use of the 
semi-quantitative  method  of  PCT  measurement  in 
URTI’s  in  the  office  setting  did  not  prove  useful, 
comes in agreement with the conclusion of the study 
of Korppi et al.
[31] who measured PCT using the LUMI 
test  procalcitonin  kit  in  children  with  Community 
Acquired Pneumonia (CAP).  
  We  found  a  correlation  of  CRP  with  body 
temperature, with higher fever resulting in higher CRP 
levels.  There  was  also  a  strong  correlation  between 
CRP  and  WBC  and  PMN  counts,  which  was 
anticipated.  CRP  was  found  to  be  more  elevated  in 
cases  of  peritonsillar  abscess  (p<0.01),  ranging  from 
1.2-24.1 mg mL
-1, whereas in tonsillopharyngitis CRP 
levels were somewhat lower. Therefore CRP could be 
used as a marker to predict the severity as well as any 
sequelae of URTI’s, although a double blind study is 
needed  to  confirm  this  finding.  Stolz  et  al.
[11]  have 
found that when the cutoff value of CRP for bacterial 
lower respiratory tract infections was set to 50 mg mL
-1 
sensitivity was 94% and specificity 72%. 
  A  limitation  of  the  present  study  was  that  the 
bacterial origin of URTIs, although clinically strongly 
suspected,  was  proven  only  in  57.5%  of  patients 
studied.  The  main  reason  which  explains  why  a 
negative  culture  was  obtained  in  nearly  half  of  our 
patients is that 45% of them had already been receiving 
antibiotics on the day of the initial examination. 
 
CONCLUSION 
 
  PCT, although promising in cases of critically ill 
patients, did not prove to be diagnostic for those with 
less severe or localized infections, such as URTI’s. In 
contrast, CRP levels were much more accurate markers 
for bacterial URTIs. It is clear that further investigation 
is  needed  to  determine  the  usefulness  of  PCT  in  the 
field of infectious diseases. Am. J. Infect. Dis., 5 (4): 282-287, 2009 
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